Global Retirement Partners LLC Purchases New Stake in Takeda Pharmaceutical Co. $TAK

Global Retirement Partners LLC purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 50,474 shares of the company’s stock, valued at approximately $780,000.

A number of other large investors have also recently made changes to their positions in TAK. Allspring Global Investments Holdings LLC grew its holdings in shares of Takeda Pharmaceutical by 3.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 22,088 shares of the company’s stock valued at $341,000 after buying an additional 715 shares during the last quarter. Sage Rhino Capital LLC lifted its position in Takeda Pharmaceutical by 7.9% in the 2nd quarter. Sage Rhino Capital LLC now owns 12,604 shares of the company’s stock valued at $195,000 after acquiring an additional 919 shares in the last quarter. Jackson Thornton Wealth Management LLC boosted its stake in Takeda Pharmaceutical by 7.8% during the 2nd quarter. Jackson Thornton Wealth Management LLC now owns 12,779 shares of the company’s stock valued at $192,000 after purchasing an additional 920 shares during the last quarter. Intelligence Driven Advisers LLC increased its holdings in Takeda Pharmaceutical by 7.2% during the 2nd quarter. Intelligence Driven Advisers LLC now owns 14,535 shares of the company’s stock worth $225,000 after purchasing an additional 977 shares in the last quarter. Finally, Ieq Capital LLC raised its stake in shares of Takeda Pharmaceutical by 4.6% in the first quarter. Ieq Capital LLC now owns 22,222 shares of the company’s stock worth $330,000 after purchasing an additional 981 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $14.52 on Friday. The stock has a 50 day moving average of $14.18 and a 200 day moving average of $14.60. The company has a market capitalization of $46.19 billion, a price-to-earnings ratio of 48.38 and a beta of 0.16. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.69. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.44. The firm had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday. Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.